Treatments for Lupus Patients Repositioned from Other Indications: Top Priority Candidates Announced by the ALR and LRI

Boston, MA — The Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) launched the Lupus Clinical Investigators Network (LuCIN) that will conduct clinical trials as part of the drug repositioning program LRxL-STAT at the American College of Rheumatology meeting. Commissioned by the ALR and LRI, and conducted in partnership with AMPEL Biosolutions, LRxL-STAT has identified and now will begin testing potential new treatments for lupus from among those approved for other human conditions.

The five highest priority candidates announced are: the small molecule quinacrine, autologous hematopoietic stem cell transplantation, the complementary and alternative krill oil treatment, and Janssen’s biologic ustekinumab. An experimental treatment in development by Kadmon is also being considered for testing. LuCIN is comprised of over 50 academic lupus centers representing all geographic regions of the U.S.

Read full press release…